Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir for prevention of CMV infection in CMV-seropositive allogeneic HSCT recipients
2013-004795-35Phase 3Completed
- Sponsor
- Chimerix Inc.
- Start
- Feb 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing Brincidofovir prophylaxis with Placebo (2 arms). Started Feb 2014; status: completed.
02
Drugs
brincidofovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2013-004795-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004795-35.